| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BJS.1800830104 |
| P698 | PubMed publication ID | 8653366 |
| P2093 | author name string | Watson SA | |
| Steele RJ | |||
| Parsons SL | |||
| P2860 | cites work | Activity of type IV collagenases in benign and malignant breast disease | Q35976755 |
| Management of carcinomas of the upper gastrointestinal tract. | Q36748415 | ||
| Sonographically guided paracentesis for palliation of symptomatic malignant ascites | Q39521512 | ||
| The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease | Q40744448 | ||
| Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer | Q41604602 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6-14 | |
| P577 | publication date | 1996-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | British Journal of Surgery | Q4970212 |
| P1476 | title | Malignant ascites | |
| P478 | volume | 83 |
| Q38855207 | A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites |
| Q77297831 | A Survey of Practice in Management of Malignant Ascites |
| Q50769683 | Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients |
| Q36065671 | Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies |
| Q58581676 | Ascites Index - an attempt to objectify the assessment of ascites |
| Q36616364 | Ascitic complement system in ovarian cancer |
| Q40202331 | Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study |
| Q38016957 | Catumaxomab: in malignant ascites |
| Q53163975 | Cirrhotic and malignant ascites: Differential CT diagnosis |
| Q86854257 | Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites |
| Q36112029 | Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone |
| Q36639217 | Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites |
| Q38183786 | Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer |
| Q35168699 | Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascites |
| Q35143498 | How valuable is ascitic cytology in the detection and management of malignancy? |
| Q37854951 | Image-Guided Palliative Care Procedures |
| Q36618164 | Immunocytochemically detected free peritoneal tumour cells (FPTC) are a strong prognostic factor in gastric carcinoma |
| Q38866773 | Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). |
| Q87412290 | Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case Report |
| Q46439804 | MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer |
| Q77196861 | Malignant ascites visualized on a radionuclide bone scan |
| Q35957129 | Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures |
| Q41001294 | Malignant ascites: a 2-year review from a teaching hospital |
| Q34213359 | Malignant ascites: pathophysiology and treatment. |
| Q35789515 | Management of ascites due to gastrointestinal malignancy |
| Q34263789 | Management of medically refractory ascites |
| Q77154385 | Metastases that interfere with circulation |
| Q51323803 | Minimal Change Nephrotic Syndrome Complicated with Malignant Ascites in a Patient with Type II Diabetes |
| Q33754724 | Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients |
| Q35057971 | Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®) |
| Q34282625 | Palliative general surgical procedures. |
| Q33892606 | Palliative treatment of malignant ascites: profile of catumaxomab |
| Q34205749 | Peritoneovenous shunting for nongynecologic malignant ascites |
| Q33885497 | Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients |
| Q74250838 | Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites |
| Q64254001 | Potential of osteopontin in the management of epithelial ovarian cancer |
| Q42383717 | Prognostic significance of new onset ascites in patients with pancreatic cancer |
| Q83061125 | Radiological Insertion of Denver Peritoneovenous Shunts for Malignant Refractory Ascites: A Retrospective Multicenter Study (JIVROSG-0809) |
| Q81652394 | Supportive care in colon cancer |
| Q41476065 | Surgical management of patients with advanced cancer (I). |
| Q37909369 | Symptom management in gynecologic malignancies |
| Q35079157 | Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report |
| Q48167974 | Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. |
| Q42710496 | Tc99m-MDP uptake in ascitic fluid in a patient with prostate carcinoma: A clue to detect metastases |
| Q34769958 | The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites |
| Q40436743 | The clinical significance of vascular endothelial growth factor in malignant ascites |
| Q92587632 | The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer |
| Q24629295 | The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial |
| Q55396474 | Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model. |
| Q78467189 | Trace elements analysis of ascitic fluid in benign and malignant diseases |
| Q44230207 | Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis |
| Q24796110 | Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide |
| Q40401963 | Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells |
| Q35811043 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells |
| Q82271411 | Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites |
| Q80234041 | [Diagnosis and treatment of peritoneal carcinoma] |
Search more.